BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29423501)

  • 21. Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool.
    Lynch PM; Morris JS; Ross WA; Rodriguez-Bigas MA; Posadas J; Khalaf R; Weber DM; Sepeda VO; Levin B; Shureiqi I
    Gastrointest Endosc; 2013 Mar; 77(3):455-63. PubMed ID: 23332604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
    Burke CA; Dekker E; Lynch P; Samadder NJ; Balaguer F; Hüneburg R; Burn J; Castells A; Gallinger S; Lim R; Stoffel EM; Gupta S; Henderson A; Kallenberg FG; Kanth P; Roos VH; Ginsberg GG; Sinicrope FA; Strassburg CP; Van Cutsem E; Church J; Lalloo F; Willingham FF; Wise PE; Grady WM; Ford M; Weiss JM; Gryfe R; Rustgi AK; Syngal S; Cohen A
    N Engl J Med; 2020 Sep; 383(11):1028-1039. PubMed ID: 32905675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry.
    Fernández-López F; Conde-Freire R; Cadarso-Suárez C; García-Iglesias J; Puente-Domínguez JL; Potel-Lesquereux J
    Eur J Surg; 2001 May; 167(5):375-81. PubMed ID: 11419555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of suindac in the treatment of familial adenomatous polyposis coli].
    Landauer S; Halimi C; Caulin C; Bergmann JF
    Therapie; 1999; 54(6):675-82. PubMed ID: 10709439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
    Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment.
    Spagnesi MT; Tonelli F; Dolara P; Caderni G; Valanzano R; Anastasi A; Bianchini F
    Gastroenterology; 1994 Feb; 106(2):362-6. PubMed ID: 8299902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulindac plus erlotinib for familial adenomatous polyposis.
    Baker H
    Lancet Oncol; 2016 May; 17(5):e183. PubMed ID: 27051970
    [No Abstract]   [Full Text] [Related]  

  • 29. [Rectal carcinoma in a patient with familial adenomatous polyposis coli after colectomy with ileorectal anastomosis and consecutive chemoprevention with sulindac suppositories].
    Utech M; Brüwer M; Buerger H; Tübergen D; Senninger N
    Chirurg; 2002 Aug; 73(8):855-8. PubMed ID: 12425165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulindac therapy of colorectal polyps in familial adenomatous polyposis.
    Tonelli F; Valanzano R; Dolara P
    Dig Dis; 1994; 12(5):259-64. PubMed ID: 7882547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
    Giardiello FM; Casero RA; Hamilton SR; Hylind LM; Trimbath JD; Geiman DE; Judge KR; Hubbard W; Offerhaus GJ; Yang VW
    Gastroenterology; 2004 Feb; 126(2):425-31. PubMed ID: 14762779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.
    Guldenschuh I; Hurlimann R; Muller A; Ammann R; Mullhaupt B; Dobbie Z; Zala GF; Flury R; Seelentag W; Roth J; Meyenberger C; Fried M; Hoppeler T; Spigelman AD; Scott RJ
    Dis Colon Rectum; 2001 Aug; 44(8):1090-7; discussion 1097-9. PubMed ID: 11535846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
    Gross ND; Bauman JE; Gooding WE; Denq W; Thomas SM; Wang L; Chiosea S; Hood BL; Flint MS; Sun M; Conrads TP; Ferris RL; Johnson JT; Kim S; Argiris A; Wirth L; Nikiforova MN; Siegfried JM; Grandis JR
    Clin Cancer Res; 2014 Jun; 20(12):3289-98. PubMed ID: 24727329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
    Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months.
    Winde G; Schmid KW; Schlegel W; Fischer R; Osswald H; Bünte H
    Dis Colon Rectum; 1995 Aug; 38(8):813-30. PubMed ID: 7634976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sulindac in familial adenomatous polyposis coli--preliminary findings of a prospective study].
    Müller A; Hürlimann R; Meyenberger C; Staub P; Kobler E; Ammann R
    Schweiz Med Wochenschr; 1994 Apr; 124(15):651-4. PubMed ID: 8191270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sulindac for periampullary polyps in FAP patients.
    Richard CS; Berk T; Bapat BV; Haber G; Cohen Z; Gallinger S
    Int J Colorectal Dis; 1997; 12(1):14-8. PubMed ID: 9112144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
    Burn J; Mathers J; Bishop DT
    Recent Results Cancer Res; 2013; 191():157-83. PubMed ID: 22893205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment with sulindac of adenomatous polyps in familial polyposis].
    Cerdán FJ; Torres-Melero J; Martínez S; Gutiérrez del Olmo A; Balibrea JL
    Rev Esp Enferm Dig; 1995 Aug; 87(8):574-6. PubMed ID: 7577106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal analysis of colon crypt stem cell dynamics in sulindac treated Familial Adenomatous Polyposis patients.
    Ma H; Brosens LAA; Elias SG; Morsink FHM; Nijman IJ; Hylind LM; Montgomery EA; Offerhaus GJA; Giardiello FM; de Leng WWJ
    Sci Rep; 2017 Sep; 7(1):11972. PubMed ID: 28931879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.